Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some dosing details match the provided label excerpt (twice daily and ~12 hours apart; concomitant use with lubricant drops with a 15-minute interval). However, multiple additional patient use/safety claims (missed-dose guidance, symptom-relief expectations, and specific urgent warning thresholds) are not supported by the provided label sections, and several dosing-context details (morning/evening) are not explicitly stated.
Category Scores
Accurate Statements
The twice-daily Restasis doses are typically about 12 hours apart.
Section 2: instill RESTASIS ophthalmic emulsion twice a day in each eye approximately 12 hours apart.
Restasis can be used concomitantly with lubricant eye drops, allowing a 15-minute interval between products.
Section 2: RESTASIS can be used concomitantly with lubricant eye drops, allowing a 15-minute interval between products.
Unsupported Statements
If a dose of Restasis is missed, it should be used when remembered unless it is close to the next scheduled dose.
No missed-dose guidance is present in the provided label excerpts (Sections shown include dosing instructions and concomitant lubricant guidance only).
If a Restasis dose is missed, two doses should not be used at once to make up for the missed dose.
No missed-dose/extra-dose prohibition is present in the provided label excerpts.
Restasis is not usually an immediate-relief eye drop.
No onset-of-effect or 'immediate-relief' characterization is present in the provided label excerpts.
Many patients need weeks to start noticing improvement with Restasis.
No patient 'weeks to improvement' statement is present in the provided label excerpts.
Artificial tears that include other medications or thicker gels should be spaced from Restasis to help prevent washout.
The provided label excerpt only supports concomitant use with lubricant eye drops with a 15-minute interval; it does not mention medicated drops, thicker gels, or a 'washout' rationale.
Prompt medical advice should be sought if there is severe eye pain, worsening redness, significant light sensitivity, or vision changes.
No such specific triage/warning criteria are present in the provided label excerpts.
Contradictions
Important Omissions
Contraindications details (hypersensitivity) and key boxed warning/warnings content were not evaluated because the provided excerpts do not include Section 4 content beyond contraindication text and do not include boxed warnings.
Importance:
Moderate
Administration/storage/handling instructions relevant to safe use (e.g., handling the unit dose vial, immediate use after opening, discarding remaining contents after administration) are not addressed in the AI claims and were not assessed here.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported guidance regarding missed doses and specific urgent symptom triage may mislead patients; however, the core labeled dosing interval and concomitant lubricant spacing are consistent with the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several patient-management and safety threshold statements are not supported by the provided label excerpts (notably missed-dose instructions, onset/relief expectations, and specific urgent symptom advice).
Suggested Improvement
Restrict claims to the provided label-supported dosing and concomitant lubricant interval language (Section 2) and remove or qualify all unsupported missed-dose, improvement-timing, onset-relief, washout rationale, and specific triage criteria statements unless supported by additional label sections not included in the prompt.